APA

Marin D., Gabriel I. H., Ahmad S., Foroni L., de Lavallade H., Clark R., O'Brien S., Sergeant R., Hedgley C., Milojkovic D., Khorashad J. S., Bua M., Alsuliman A., Khoder A., Stringaris K., Cooper N., Davis J., Goldman J. M., Apperley J. F. & Rezvani K. (20120330). KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. : Leukemia.

Chicago

Marin D, Gabriel I H, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad J S, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman J M, Apperley J F and Rezvani K. 20120330. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. : Leukemia.

Harvard

Marin D., Gabriel I. H., Ahmad S., Foroni L., de Lavallade H., Clark R., O'Brien S., Sergeant R., Hedgley C., Milojkovic D., Khorashad J. S., Bua M., Alsuliman A., Khoder A., Stringaris K., Cooper N., Davis J., Goldman J. M., Apperley J. F. and Rezvani K. (20120330). KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. : Leukemia.

MLA

Marin D, Gabriel I H, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad J S, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman J M, Apperley J F and Rezvani K. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. : Leukemia. 20120330.